ATS 2019 Virtual Final Program

trying to increase access to and reach of lung cancer screening, and successful strategies implemented to overcome these barriers. Chairing: R.S. Wiener, MD, MPH, Boston, MA M.P. Rivera, MD, ATSF, Chapel Hill, NC J.P. Wisnivesky, DrPH, MD, New York, NY 9:15 Overview: Why Are so Few Eligible Individuals Screened? R.S. Wiener, MD, MPH, Boston, MA 9:20 Promoting Quality but Limiting Access? Impact of Policy Coverage Decisions M.S. Kale, MD, MPH, New York, NY 9:40 Lightening the Load: Helping PCPs Identify Eligible Patients and Facilitate Shared Decision-Making T. Caverly, MD, MPH, Ann Arbor, MI 10:00 Overcoming Patient-Level Barriers: Addressing Stigma Experienced by Smokers L. Carter-Harris, PhD, APRN, ANP-C, New York, NY 10:20 Public Health Outreach: Kentucky’s Terminate Lung Cancer Campaign R. Cardarelli, DO, MPH, Lexington, KY 10:40 Integrating and Coordinating Health Care in Inner City Communities R.A. Winn, PhD, Chicago, IL 11:00 Working Together to Turn the Tide R.A. Smith, PhD, Atlanta, GA This session and the International Conference are supported by an educational grant from AstraZeneca LP. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 B9 ADDICTING A NEW GENERATION: JUULING, VAPING, HEAT NOT BURN, FLAVORINGS, AND THE EVIDENCE FOR WHY WE SHOULD BE VERY CONCERNED Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Pediatrics; Respiratory Cell and Molecular Biology; Thoracic Oncology 9:15 a.m. - 11:15 a.m. KBHCCD Room D220/D227 (Level 2) Target Audience Health care providers and trainees, public policy advocates and decision makers, tobacco and e-cigarette researchers. Objectives At the conclusion of this session, the participant will be able to: • describe how to assess harm reduction and different elements that need to go into a harm reduction claim; • counsel patients and educate the general public about the substantial harms of electronic nicotine delivery systems; • describe and effectively advocate for evidenced based public policy initiatives that can protect young people from new tobacco products, including electronic nicotine delivery systems. New tobacco products are coming on the market with implied claims of reduced harm, however many of these claims do not seem to have any more solid of an evidence base as the false claims of reduced harm for low tar and nicotine cigarettes. This session will review principles of assessing claims of harm reduction, the evidence on how these new tobacco products harm users, addicts non-users, and servers as an entry to use of other tobacco products by young people. Evidence based public policy recommendations will be discussed. Chairing: E.R. Neptune, MD, Baltimore, MD D.J. Upson, MD, MA, Albuquerque, NM S. Pakhale, MD, MSCE, Ottawa, Canada 9:15 Verities and Balderdash About Harm Reduction and the New ATS Policy to Support a Comprehensive Evidence-Based Approach F.T. Leone, MD, MS, ATSF, Philadelphia, PA 9:35 New and Emerging Tobacco Products: What Are the Harms? Juul/Vapes/E-Cigs/Heat Not Burn I. Jaspers, PhD, Chapel Hill, NC 9:55 Electronic Nicotine Delivery Systems (E-Cigarettes) Are Addicting a New Generation: Why We Should Worry H.J. Farber, MD, MSPH, ATSF, Houston, TX 10:14 New Tobacco Products and Tobacco Control in Latin America G.E. Zabert, MD, Neuquén, Argentina 10:34 Disparities in Tobacco and Nicotine Promotion and Addiction: How Can Marginalized Populations Be Protected? S. Pakhale, MD, MSCE, Ottawa, Canada 10:53 Video Presentation: Juulers against Juul H.J. Farber, MD, MSPH, ATSF, Houston, TX 10:59 FDA Policy Initiatives to Protect Youth From Nicotine and Tobacco: Where Do We Stand? M. Zeller, JD, Silver Spring, MD BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 0 B10 HUMAN LUNG CELL ATLAS: BEYOND SINGLE CELL RNA-SEQUENCING Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Section of Genetics and Genomics 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D One (Level 3) ATS 2019 • Dallas, TX MONDAY • MAY 20 127 MONDAY MORNING